Gilead accused of illegally paying to delay HIV drug competition
Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 August 2022 Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.
4 November 2020 Gilead Sciences has claimed that a group of Florida-based healthcare clinics, pharmacies, and lab testing facilities have “wrongfully captured tens of millions of dollars” through a fraudulent programme.
22 August 2019 Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
